IMMUNOHISTOCHEMISTRY, P63

The IHC – P63 test is an immunohistochemistry-based diagnostic assay used to detect p63 protein expression in tissue samples. P63 is a nuclear transcription factor that plays an important role in the development and maintenance of epithelial tissues, especially basal and squamous epithelial cells.

This test is widely used in pathology to diagnose and classify squamous cell carcinomas, basal cell tumors, and various epithelial neoplasms. P63 staining helps pathologists identify squamous differentiation and distinguish epithelial tumors from non-epithelial malignancies.

Benefits of the Test

• Helps diagnose squamous cell carcinoma
• Assists in identifying epithelial tumor origin
• Differentiates squamous tumors from adenocarcinomas
• Supports accurate tumor classification
• Helps guide oncology treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC P63 test when there is suspicion of epithelial or squamous-origin tumors. It is commonly used in:

• Diagnosis of squamous cell carcinoma
• Lung cancer subtype classification
• Head and neck tumor evaluation
• Prostate and urothelial pathology studies
• Differentiation of epithelial malignancies

P63 is frequently used along with markers such as CK5/6, p40, TTF-1, and cytokeratins to achieve precise diagnosis and tumor classification.

Preparation Before Test

No special preparation is required from the patient. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are necessary
• Clinical findings and imaging studies support interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on laboratory workflow and tissue processing requirements.

Who Should Take This Test

• Patients with suspected squamous cell carcinoma
• Individuals with epithelial tumors of unknown origin
• Lung tumor classification cases
• Head and neck cancer evaluations
• Oncology patients requiring tumor subtype confirmation

The IHC P63 test is an important tool in modern surgical pathology. It helps identify squamous and basal cell differentiation accurately, supporting early diagnosis and effective treatment planning for epithelial cancers.